



General Assembly

January Session, 2025

Raised Bill No. 1473

LCO No. 5674



Referred to Committee on HUMAN SERVICES

Introduced by:
(HS)

***AN ACT REQUIRING MEDICAID COVERAGE FOR FDA-APPROVED
GENE THERAPIES TO TREAT SICKLE CELL DISEASE.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective from passage*) (a) The Commissioner of
2 Social Services shall provide Medicaid coverage for gene therapies
3 approved by the federal Food and Drug Administration to treat sickle
4 cell disease.

5 (b) The commissioner shall apply for any federal initiative to increase
6 cost-effective access to the therapies, including, but not limited to, the
7 Cell and Gene Therapy Access Model administered by the Centers for
8 Medicare and Medicaid Services.

9 (c) Not later than January 1, 2026, the commissioner shall file a report,
10 in accordance with the provisions of section 11-4a of the general statutes,
11 with the joint standing committee of the General Assembly having
12 cognizance of matters relating to human services on the (1) efforts to
13 increase cost-effective access to the therapies, (2) number of Medicaid
14 recipients who have received Medicaid coverage for the therapies, (3)
15 cost to the state to provide such therapies, and (4) estimated state

16 appropriations needed to provide such coverage.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>from passage</i>	New section

Statement of Purpose:

To require Medicaid coverage for gene therapies approved by the federal Food and Drug Administration to treat sickle cell disease.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]